

The Pro Debate References

1. Carvalho JR, Verdelho Machado M. New Insights About Albumin and Liver Disease. *Ann Hepatol.* 2018;17(4):547-560
2. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. *Hepatology.* 2013;58(5):1836-1846
3. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2021;74(2):1014-1048
4. Jagdish RK, Maras JS, Sarin SK. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!. *Hepatology.* 2021;74(5):2848-2862
5. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J Hepatol.* 1999;30(4):639-645
6. Fernández J, Clària J, Amorós A, et al. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. *Gastroenterology.* 2019;157(1):149-162
7. China L, Freemantle N, Forrest E, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. *N Engl J Med.* 2021;384(9):808-817
8. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. *World J Gastroenterol.* 2006;12(9):1403-1407
9. Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. *Liver Int.* 2019;39(1):98-105
10. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial [published correction appears in *Lancet.* 2018 Aug 4;392(10145):386]. *Lancet.* 2018;391(10138):2417-2429
11. Bajaj JS, Tandon P, O'Leary JG, et al. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. *Am J Gastroenterol.* 2018;113(9):1339

The Con Debate References

1. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the american association for the study of liver diseases. *Hepatology.* 2021;74:1014-48.

2. Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. *J Hepatol.* 2018;69(6):1250-59. doi:10.1016/j.jhep.2018.08.006
3. China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. *N Engl J Med.* 2021;384:808-17.
4. Bajaj JS, Tandon P, O'Leary JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. *Am J Gastroenterol.* 2018;113(9):1339. doi:10.1038/s41395-018-0119-3
5. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet.* 2018;391(10138):2417-29. doi:10.1016/S0140-6736(18)30840-7
6. Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. *Am J Gastroenterol.* 2020;115(11):1775-1785. doi:10.14309/ajg.0000000000000786

Clinical Review References: An Overview of SGLT2i in HFpEF and HFrEF

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022; 145:e895.
2. Schwinger RHG. Pathophysiology of heart failure. *Cardiovasc Diagnostic Ther.* 2021;11(1):263-276. doi:10.21037/cdt-20-302
3. Simmonds SJ, Cuijpers I, Heymans S, et al. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. *Cells* 2020;9:242. doi:10.3390/cells9010242
4. Griffin, M, Rao, VS, Ivey-Miranda, J, et al. (2020). Empagliflozin in heart failure: diuretic and cardiorenal effects. *Circulation*, 142(11), 1028-1039.
5. Samuel, E. Sodium-Glucose Cotransporter 2 Inhibitors: An Overview. *U.S. Pharmacist – The Leading Journal in Pharmacy*, 13 Oct. 2017.
6. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *New England Journal of Medicine.* 2019;381(21):1995-2008.

7. Packer M, Anker SD, Butler J, *et al.* Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *New England Journal of Medicine*. 2020;383(15):1413-1424.
8. Solomon SD, de Boer RA, DeMets D, *et al.* Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *European Journal of Heart Failure*. 2021;23(7):1217-1225.
9. Solomon, SD, McMurray, JJ, Claggett, B, *et al.* (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *New England Journal of Medicine*, 387(12), 1089-1098.
10. Anker SD, Butler J, Filippatos G, *et al.* Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *New England Journal of Medicine*. 2021;385(16):1451-1461.
11. Lexi-Comp Online. Hudson, Ohio: Lexi-Comp, Inc.; Jan 17, 2023.